Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 17Genitourinary 6Thoracic 5Gastrointestinal 5Lymphoid 4Dermatologic 4Gynecologic 3CNS 3Sarcoma 2Myeloid 2Head & Neck 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Endocrine 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 39Leukemia, Myeloid, Acute 35Myelodysplastic Syndromes 33Lymphoma, Non-Hodgkin 27Leukemia, Lymphocytic, Chronic, B-Cell 25Hodgkin Disease 25Leukemia 24Graft vs Host Disease 23Lymphoma 20Hematologic Neoplasms 20Multiple Myeloma 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Lymphoma, Mantle-Cell 16Myeloproliferative Disorders 15Lymphoma, Large B-Cell, Diffuse 15Burkitt Lymphoma 14Lymphoma, Follicular 13Waldenstrom Macroglobulinemia 12Lymphoma, B-Cell, Marginal Zone 12Primary Myelofibrosis 11Leukemia, Myelomonocytic, Chronic 11Leukemia, Myeloid, Chronic-Phase 10Leukemia, Myeloid, Accelerated Phase 10Blast Crisis 10Congenital Abnormalities 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Neoplasms, Plasma Cell 8Lymphoma, Large-Cell, Immunoblastic 8Myelodysplastic-Myeloproliferative Diseases 7Leukemia, Prolymphocytic 7

Interventions

Cyclophosphamide 7Therapeutics 6Flow Cytometry 6Radiotherapy 4Peripheral Blood Stem Cell Transplantation 4Filgrastim 4Psychiatric Rehabilitation 3Polymerase Chain Reaction 3Paclitaxel 3Immunologic Techniques 3Immunoenzyme Techniques 3Doxorubicin 3Carboplatin 3Amplified Fragment Length Polymorphism Analysis 3venetoclax 2trametinib 2temsirolimus 2sargramostim 2ruxolitinib 2pertuzumab 2pembrolizumab 2palbociclib 2liposomal doxorubicin 2liposomal amphotericin B 2dabrafenib 2copanlisib 2bosutinib 2aldesleukin 2abiraterone 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Sirolimus × Other hematologic neoplasm × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡